Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;36(5):781-813.
doi: 10.1007/s11011-021-00673-z. Epub 2021 Feb 27.

Metabolic disorder in Alzheimer's disease

Mrinal K Poddar  1 , Soumyabrata Banerjee  2   3 , Apala Chakraborty  2 , Debasmita Dutta  2   4
Affiliations
Review

Metabolic disorder in Alzheimer's disease

Mrinal K Poddar et al. Metab Brain Dis. 2021 Jun.

Abstract

Alzheimer's disease (AD), a well known aging-induced neurodegenerative disease is related to amyloid proteinopathy. This proteinopathy occurs due to abnormalities in protein folding, structure and thereby its function in cells. The root cause of such kind of proteinopathy and its related neurodegeneration is a disorder in metabolism, rather metabolomics of the major as well as minor nutrients. Metabolomics is the most relevant "omics" platform that offers a great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome. In recent years, the research on such kinds of neurodegenerative diseases, especially aging-related disorders is broadened its scope towards metabolic function. Different neurotransmitter metabolisms are also involved with AD and its associated neurodegeneration. The genetic and epigenetic backgrounds are also noteworthy. In this review, the physiological changes of AD in relation to its corresponding biochemical, genetic and epigenetic involvements including its (AD) therapeutic aspects are discussed.

Keywords: Alzheimer’s disease; Biochemical changes; Genetic changes; Metabolic disorder; Neurodegeneration.

PubMed Disclaimer

References

    1. Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B (2017) EU/US/CTAD task force: lessons learned from recent and current alzheimer’s prevention trials. J Prev Alzheimers Dis 4:116–124 - PubMed - PMC
    1. Alkalay A, Rabinovici GD, Zimmerman G, Agarwal N, Kaufer D, Miller BL, Jagust WJ, Soreq H (2013) Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res 10:48–56 - PubMed - PMC
    1. Alzheimer’s Association (2020) https://www.alz.org/alzheimers-dementia/research_progress/treatment-horizon . Accessed 20 Oct 2020
    1. Alzheimer’s society (2020) https://www.alzheimers.org.uk/about-us/policy-and-influencing/what-we-th...
    1. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CAF, BreiderhoffT JP, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer AA, Willnow TE (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Nat Acad Sci (USA) 102:13461–13466 - DOI

LinkOut - more resources